NSE / BSEHealthcare
β‚Ή2618.15+67.10+2.63%
P/E54.8Mkt Capβ‚Ή91.28 K CrEV/EBITDA34.3

Mankind Pharma Limited

P/E54.8Mkt Capβ‚Ή91.28 K CrEV/EBITDA34.3
Company Profile

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 3.03% over 1Y
Monthly Returns

Historically, Aug has averaged the highest return (+6.2%); Jan the lowest (-5.9%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-3.3%Negative MonthJan 2026: -3.25%+5.8%Positive MonthFeb 2026: +5.78%-10.8%Negative MonthMar 2026: -10.76%+12.0%Positive MonthApr 2026: +12.00%+10.4%Positive MonthMay 2026: +10.41%+2.7%Positive MonthJun 2026: +2.66%+2.8%*Positive MonthJul 2026: +2.81%β€”β€”β€”β€”β€”
2025-15.4%Negative MonthJan 2025: -15.39%-6.0%Negative MonthFeb 2025: -6.03%+5.8%Positive MonthMar 2025: +5.81%+1.7%Neutral MonthApr 2025: +1.67%+0.4%Neutral MonthMay 2025: +0.40%-6.1%Negative MonthJun 2025: -6.10%+10.5%Positive MonthJul 2025: +10.55%-3.8%Negative MonthAug 2025: -3.75%-1.4%Neutral MonthSep 2025: -1.40%-2.2%Negative MonthOct 2025: -2.24%-5.5%Negative MonthNov 2025: -5.48%-2.5%Negative MonthDec 2025: -2.46%
2024+0.8%Neutral MonthJan 2024: +0.83%+6.8%Positive MonthFeb 2024: +6.80%+7.6%Positive MonthMar 2024: +7.58%+3.0%Positive MonthApr 2024: +2.99%-9.3%Negative MonthMay 2024: -9.30%-0.8%Neutral MonthJun 2024: -0.82%-4.6%Negative MonthJul 2024: -4.57%+22.5%Positive MonthAug 2024: +22.49%+1.3%Neutral MonthSep 2024: +1.35%+5.8%Positive MonthOct 2024: +5.75%-3.9%Negative MonthNov 2024: -3.91%+12.4%Positive MonthDec 2024: +12.41%
2023β€”β€”β€”β€”β€”+25.6%Positive MonthJun 2023: +25.62%+6.3%Positive MonthJul 2023: +6.34%-0.2%Neutral MonthAug 2023: -0.23%-0.9%Neutral MonthSep 2023: -0.95%-2.9%Negative MonthOct 2023: -2.90%+8.2%Positive MonthNov 2023: +8.24%+5.2%Positive MonthDec 2023: +5.22%
AvgΒ±SD-5.9%Β±6.9%+2.2%Β±5.8%+0.9%Β±8.3%+5.6%Β±4.6%+0.5%Β±8.0%+5.3%Β±12.1%+3.8%Β±5.5%+6.2%Β±11.6%-0.3%Β±1.2%+0.2%Β±3.9%-0.4%Β±6.1%+5.1%Β±6.1%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 4 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.192x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή9.50 K Crβ–² 10.1%
EBITDA Growthβ€”
Net Profitβ‚Ή1.95 K Crβ–² 3.7%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 120.0%
Revenue CAGR 5Y12.5%
EBITDA CAGR 5Y14.6%
Net Profit CAGR 5Y14.4%
NP Growth 1Y3.7%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή9.50 K Crβ€”β‚Ή1.95 K Crβ€”β€”13.3%10.1%3.7%
Mar 2024β‚Ή8.63 K Crβ€”β‚Ή1.88 K Crβ€”β€”19.3%6.2%50.3%
Mar 2023β‚Ή8.13 K Crβ€”β‚Ή1.25 K Crβ€”β€”16.0%8.6%-10.2%
Mar 2022β‚Ή7.49 K Crβ€”β‚Ή1.39 K Crβ€”β€”21.2%35.4%28.1%
Mar 2021β‚Ή5.53 K Crβ€”β‚Ή1.08 K Crβ€”β€”22.9%15.4%13.2%
Mar 2020β‚Ή4.79 K Crβ€”β‚Ή958.00 Crβ€”β€”26.2%25.2%86.4%
Mar 2019β‚Ή3.83 K Crβ€”β‚Ή514.00 Crβ€”β€”16.8%-2.3%-25.9%
Mar 2018β‚Ή3.92 K Crβ€”β‚Ή694.00 Crβ€”β€”23.2%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales3,9183,8294,7945,5307,4868,1278,6299,4989,691
Total Expenses3,1413,1243,5504,1515,6446,4296,3586,9307,102
EBIT / Operating Profit7787051,2441,3791,8421,6982,2722,5672,589
OPM %20%18%26%25%25%21%26%27%27%
Other Income2096494148200163369550432
Finance Costs1840118482817372656
Depreciation & Amortisation28386278123270335378392
Profit Before Tax9416911,2651,4401,8711,5632,2892,3671,972
Tax %26%26%24%25%26%20%18%18%-
Net Profit / PAT6945149581,0841,3891,2481,8761,9451,666
EPS (β‚Ή)17.3312.8323.9227.0734.6831.1646.8447.1540.38
Dividend Payout %0%0%32%0%0%0%0%0%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Mankind Pharma Limitedthis co.β‚Ή91.28 K Crβ‚Ή9.50 K Cr54.805.8934.3110.1%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Mankind Pharma Limited and the metrics that matter.

Browse the full Equiscale Academy